Andrew Bellinger, Chief Scientific Officer at Verve Therapeutics, Inc. (VERV), bought 5,000 shares at $19.00 ($95K) on 2021-06-21, disclosed to the SEC on 2021-06-21.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| VERV | SELL | 2022-09-27 | $4.2M | — | Filing → |
| VERV | SELL | 2022-07-22 | $698K | — | Filing → |
| VERV | SELL | 2022-07-15 | $249K | — | Filing → |